Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials

Bibliography

• Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42
   PubMed Web of Science ®Google Scholar
• Schuurman HJ, Schuler W, Ringers J, Jonker M. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 1998;30:2198-9
   PubMed Web of Science ®Google Scholar
• Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998;30:2200-3
   PubMed Web of Science ®Google Scholar
• Vítko S, Margreiter R, Weimar W, et al. RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5:2521-30
   PubMed Web of Science ®Google Scholar
• Lorber MI, Mulgaonkar S, Butt KM, et al. B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, Phase III study. Transplantation 2005;80:244-52
   PubMed Web of Science ®Google Scholar
• Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004;4:626-35
   PubMed Web of Science ®Google Scholar
• Viganò M, Tuzcu M, Benza R, et al. RAD B253 Study Group. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007;26:584-92
   PubMed Web of Science ®Google Scholar
• Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-6
   PubMed Web of Science ®Google Scholar
• Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol 1977;55:48-51
   PubMed Web of Science ®Google Scholar
• Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989;17:609-10
   Google Scholar
• Calne RY, Lim S, Saaman A, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989;2:227
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253:905-9
   PubMed Web of Science ®Google Scholar
• Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998;10:330-6
   PubMed Web of Science ®Google Scholar
• Sabers C, Martin M, Brunn G, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995;270:815-22
   PubMed Web of Science ®Google Scholar
• Sabatini D, Erdjument-Bromage H, Lui M, et al. A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78:35-43
   PubMed Web of Science ®Google Scholar
• Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Ann Rev Immunol 1996;14:483-510
   PubMed Web of Science ®Google Scholar
• Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999;10:1366-80
   PubMed Web of Science ®Google Scholar
• Rovira P, Mascarell L, Truffa Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem 2000;7:673-92
   PubMed Web of Science ®Google Scholar
• Crowe A, Bruelisauer A, Duerr L, et al. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999;27:627-32
   PubMed Web of Science ®Google Scholar
• Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999;48:694-703
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Winkler M, Mueller L, et al. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 2000;50:449-54
   PubMed Web of Science ®Google Scholar
• Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone–treated renal transplant recipients. Transplantation 1999;68:1100-6
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relation-ships, and influence on cyclosporine. Clin Pharmacol Ther 2001;69:48-56
   PubMed Web of Science ®Google Scholar
• Laplanche R, Meno-Tetang GM, Kawai R. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J Pharmacokinet Pharmacodyn 2007;34:373-400
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001;33:514-5
   PubMed Web of Science ®Google Scholar
• Vidal C, Kirchner GI, Sewing KF. Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD. J Am Soc Mass Spectrom 1998;9:1267-74
   PubMed Web of Science ®Google Scholar
• Hallensleben K, Raida M, Habermehl G. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J Am Soc Mass Spectrom 2000;11:516-25
   PubMed Web of Science ®Google Scholar
• Lhoëst G, Hertsens R, Verbeeck RK, et al. In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry. J Mass Spectrom 2001;36:889-90
   PubMed Web of Science ®Google Scholar
• Strom T, Haschke M, Zhang YL, et al. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther Drug Monit 2007;29:592-9
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002;22:154-9
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001;70:247-54
   PubMed Web of Science ®Google Scholar
• Van Damme-Lombaerts R, Webb NA, Hoyer PF, et al. Everolimus Study Group. Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant 2002;6:147-52
   PubMed Web of Science ®Google Scholar
• Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus Pediatric Study Group. Everolimus in pediatric de novo renal transplant patients. Transplantation 2003;75:2082-5
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002;42:95-9
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Curtis JJ, Hricik DE, et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006;38:3456-8
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Beyer D, Bizot MN, et al. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005;60:434-7
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Beyer D, Bizot MN, et al. Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol 2005;61:35-8
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Beyer D, Bizot MN, et al. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005;45:514-8
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002;36:981-5
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006;27:421-6
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001;70:425-3
   PubMed Web of Science ®Google Scholar
• Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005;19:145-52
   PubMed Web of Science ®Google Scholar
• Strom T, Haschke M, Boyd J, et al. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit 2007;29:743-9
   PubMed Web of Science ®Google Scholar
• Salm P, Warnholtz C, Boyd J, et al. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem 2006;39:732-8
   PubMed Web of Science ®Google Scholar
• Tenderich G, Fuchs U, Zittermann A, et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007;21:536-43
   PubMed Web of Science ®Google Scholar
• Mueller MA, Beutner F, Teupser D, et al. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR(-/-) mice despite severe hypercholesterolemia. Atherosclerosis 2007 [Epub ahead of print]
   Google Scholar
• Tedesco-Silva H Jr, Vitko S, Pascual J, et al. 2306 and 2307 study groups. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007;20:27-36
   PubMed Web of Science ®Google Scholar
• Montagnino G, Sandrini S, Iorio B, et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2007 [Epub ahead of print]
   PubMedGoogle Scholar
• Sánchez Fructuoso A, Calvo N, Moreno MA, et al. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transplant Proc 2007;39:2242-4
   PubMed Web of Science ®Google Scholar
• Thaunat O, Beaumont C, Chatenoud L, et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence chronic inflammatory state. Transplantation 2005;80:1212
   PubMed Web of Science ®Google Scholar
• Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004;77:1555-61
   PubMed Web of Science ®Google Scholar
• Rothenburger M, Zuckermann A, Bara C, et al. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007;26:305-11
   PubMed Web of Science ®Google Scholar
• McTaggart RA, Tomlanovich S, Bostrom A, et al. Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation 2004;78:475-80
   PubMed Web of Science ®Google Scholar
• Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008;85:486-90
   PubMed Web of Science ®Google Scholar
• McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003;3:416
   PubMed Web of Science ®Google Scholar
• Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003;14:1037
   PubMed Web of Science ®Google Scholar
• Fuller TF, Freise CE, Serkova N, et al. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003;76:1594
   PubMed Web of Science ®Google Scholar
• Loverre A, Ditonno P, Crovace A, et al. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. J Am Soc Nephrol 2004;15:2675
   PubMed Web of Science ®Google Scholar
• Pallet N, Thervet E, Le Corre D, et al. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int 2005;67:2422
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75
   PubMed Web of Science ®Google Scholar
• David S, Kümpers P, Shin H, et al. Everolimus-associated interstitial pneumonitis in a patient with a heart transplant. Nephrol Dial Transplant 2007;22:3363-4
   PubMed Web of Science ®Google Scholar
• Morelon E, Stern M, Israël-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72:787-90
   PubMed Web of Science ®Google Scholar
• Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215-20
   PubMed Web of Science ®Google Scholar
• Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004;79:541-5
   PubMed Web of Science ®Google Scholar
• Pascual J. Everolimus in clinical practice: renal transplantation. Nephrol Dial Transplant 2006;21(Suppl 3):iii18-23
   PubMedGoogle Scholar
• Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus induced pneumonitis after conversion to everolimus. Transplant Proc 2006;38:711-3
   PubMed Web of Science ®Google Scholar
• Lehmkuhl H, Ross H, Eisen H, Valantine H. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005;37:4145-9
   PubMed Web of Science ®Google Scholar
• Franco AF, Martini D, Abensur H, Noronha IL. Proteinuria in transplant patients associated with SRL. Transplant Proc 2007;39:449-52
   PubMed Web of Science ®Google Scholar
• Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Early SRL use with cyclosporine elimination does not induce progressive proteinuria. Transplant Proc 2007;39:2151-2
   PubMed Web of Science ®Google Scholar
• Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008;8:854-61
   PubMed Web of Science ®Google Scholar
• van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006;70:1355-7
   PubMed Web of Science ®Google Scholar
• Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006;2:488-93
   Google Scholar
• Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006;2:429-33
   Google Scholar
• Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004;17:215-20
   PubMed Web of Science ®Google Scholar
• Schwarz C, Bohmig GA, Steininger R, et al. Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol Dial Transplant 2001;16:378-82
   PubMed Web of Science ®Google Scholar
• Vogelbacher R, Wittmann S, Braun A, et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007;84:1492-9
   PubMed Web of Science ®Google Scholar
• Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-706
   PubMed Web of Science ®Google Scholar
• Coombes JD, Mreich E, Liddle C, Rangan GK. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 2005;68:2599-607
   PubMed Web of Science ®Google Scholar
• MacWay F, Coté I, Latulippe E, et al. Predisposing factors for sirolimus-induced proteinuria in renal transplant recipients [abstract]. Am J Transplant 2007;7(Suppl 2):246
   Google Scholar
• Tuzuner A, Mead H, Sar A, et al. Clinical predictors for proteinuria development in patients converted to sirolimus base therapy [abstract]. Am J Transplant 2007;7(Suppl 2):447
   Google Scholar
• Steele GH, Adamkovic AB, Demopoulos LA, et al. Pericardial effusion coincident with airolimus therapy: a review of Wyeth's safety database. Transplantation 2008;85:645-7
   PubMed Web of Science ®Google Scholar
• Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008;85:821-6
   PubMed Web of Science ®Google Scholar
• Viklicky O, Zou H, Mueller V, et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000;69:497-502
   PubMed Web of Science ®Google Scholar
• Lutz J, Zou H, Liu S, et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003;76:508-15
   PubMed Web of Science ®Google Scholar
• Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin; the discovery of SDZ-RAD. Transplant Proc 1998;30:2192-4
   PubMed Web of Science ®Google Scholar
• Salas-Prato M, Assalian A, Mehdi AZ, et al. Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro. J Glaucoma 1996;5:54-9
   PubMed Web of Science ®Google Scholar
• Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004;77:275-80
   PubMed Web of Science ®Google Scholar
• Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int 2008;21:2-10
   PubMed Web of Science ®Google Scholar
• Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to SRL for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006;82:1153-62
   PubMed Web of Science ®Google Scholar
• Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to SRL in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006;21:562-8
   PubMed Web of Science ®Google Scholar
• Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with SRL-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007;7:1572-83
   PubMed Web of Science ®Google Scholar
• Kamar N, Frimat L, Blancho G, et al. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to SRL-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency. Transpl Int 2007;20:128-34
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang W, Gu M, et al. Protective effects of SRL by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. Transplant Proc 2007;39:1410-5
   PubMed Web of Science ®Google Scholar
• Saber LT, Ikeda MY, Almeida JM. Posttransplantation conversion to SRL-based immunosuppression: a single center experience. Transplant Proc 2007;39:3098-100
   PubMed Web of Science ®Google Scholar
• Diekmann F, Budde K, Slowinski T, et al. Conversion to SRL for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transpl Int 2008;21:152-5
   PubMed Web of Science ®Google Scholar
• Basu A, Falcone JL, Tan HP, et al. Chronic allograft nephropathy score before SRL rescue predicts allograft function in renal transplant patients. Transplant Proc 2007;39:94-8
   PubMed Web of Science ®Google Scholar
• Sánchez Fructuoso A, Ruiz San Millán JC, Calvo N, et al. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients. Transplant Proc 2007;39:2148-50
   PubMed Web of Science ®Google Scholar
• Ruiz JC, Sanchez-Fructuoso A, Rodrigo E, et al. Conversion to everolimus in kidney transplant recipients: a safe and simple procedure. Transplant Proc 2006;38:2424-6
   PubMed Web of Science ®Google Scholar
• Wirnsberger GH, Mauric A, Worm H, et al. Improvement of renal graft function after conversion to everolimus in long-term transplanted patients [abstract]. Transpl Int 2007;20(Suppl 2):255
   Google Scholar
• Pape L, Ahlenstiel T, Ehrich JH, Offner G. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 2007;11:291-5
   PubMed Web of Science ®Google Scholar
• Morales J, Fierro A, Benavente D, et al. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. Transplant Proc 2007;39:591-3
   PubMed Web of Science ®Google Scholar
• Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to SRL in chronic allograft dysfunction. Am J Transplant 2004;4:1869-75
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Nissen SE. New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, MD. Circulation 2006;113:e394-5
   PubMed Web of Science ®Google Scholar
• Wang S, Zuckermann A, Keogh AM, et al. Cyclosporine reduction in the presence of concentration-controlled everolimus in de novo cardiac transplantation: 6-month study results [abstract]. Transpl Int 2007;20(Suppl 2):94
   Google Scholar
• Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53
   PubMed Web of Science ®Google Scholar
• Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694-700
   PubMed Web of Science ®Google Scholar
• Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006;16:46-51
   PubMed Web of Science ®Google Scholar
• Ross HJ, Burton J, Pflugfelder R, et al. Canadian pilot study to determine safe and effective dosing of cyclosporine and everolimus in stable cardiac transplant recipients: twelve-week interim analysis [abstract]. J Heart Lung Transplant 2006;25:166
   Google Scholar
• Trosch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004;52:163-8
   PubMed Web of Science ®Google Scholar
• Snell GI, Levvey BJ, Chin W, et al. Rescue therapy: a role for sirolimus in lung and heart transplant recipients. Transplant Proc 2001;33:1084-5
   PubMed Web of Science ®Google Scholar
• Bestetti R, Theodoropoulos TA, Burdmann EA, et al. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients inthe midterm follow-up. Transplantation 2006;81:692-6
   PubMed Web of Science ®Google Scholar
• Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, et al. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center. Transplant Proc 2005;37:4021-3
   PubMed Web of Science ®Google Scholar
• Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac transplant recipients with chronic renal failure. Transplantation 2004;77:568-74
   PubMed Web of Science ®Google Scholar
• Hunt J, Lerman M, Magee MJ, et al. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 2005;24:1863-7
   PubMed Web of Science ®Google Scholar
• Rothenburger M, Strypmann J, Welp H, et al. Calcineurin inhibitor-free immunosuppression using everolimus in long term heart transplant recipients: procedures of switching protocols and side effects [abstract]. J Heart Lung Transplant 2006;25:166
   Google Scholar
• Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005;24:2129-36
   PubMed Web of Science ®Google Scholar
• Moro J, Almenar L, Martínez-Dolz L, et al. mTOR inhibitors: do they help preserve renal function? Transplant Proc 2007;39:2135-7
   PubMed Web of Science ®Google Scholar
• MacDonald AS. Use of mTOR inhibitors in human organ transplantation. Expert Rev Clin Immunol 2007;3:423-36
   PubMedGoogle Scholar
• Hummel M. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J Heart Lung Transplant 2005;24(Suppl 4):S196-200
   PubMed Web of Science ®Google Scholar
• Bocchi EA, Ahualli L, Amuchastegui M, et al. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting. Transplant Proc 2006;38:937-4
   PubMed Web of Science ®Google Scholar
• Fiocchi R, Iacovoni A, Sebastiani R, et al. Possible role of everolimus in improving renal function in long-term heart transplantation. Transplant Proc 2007;39:1967-9
   PubMed Web of Science ®Google Scholar
• Snell GI, Valentine VG, Vitulo P, et al. RAD B159 Study Group. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006;6:169-77
   PubMed Web of Science ®Google Scholar
• Levy GA, Grant D, Paradis K, et al. Pharmacokinetics and tolerability of 40-0[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001;71:160-3
   PubMed Web of Science ®Google Scholar
• Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006;12:1640-8
   PubMed Web of Science ®Google Scholar
• Rapamune oral solution – Sirolimus – Wyeth Pharmaceuticals. In: Physician desk reference 2003. 57th edition. Montvale, NJ: Thomson Healthcare; 2003. p. 3469-74
   Google Scholar
• Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and metaanalysis of randomized trials. Transplantation 2006;81:1234-48
   PubMed Web of Science ®Google Scholar
• Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007;84:1436-42
   PubMed Web of Science ®Google Scholar
• Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007;26:557-64
   PubMed Web of Science ®Google Scholar
• Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007;13:433-42
   PubMed Web of Science ®Google Scholar
• Albanell J, Dalmases A, Rovira A, Rojo F. mTOR signalling in human cancer. Clin Transl Oncol 2007;9:484-93
   PubMed Web of Science ®Google Scholar
• Seeliger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26:611-21
   PubMed Web of Science ®Google Scholar
• Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35
   PubMed Web of Science ®Google Scholar
• Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027
   PubMed Web of Science ®Google Scholar
• Boulay A, Stephan C, Zumstein-Mecker S. Phospho-Akt levels as a potential biomarker of in vitro sensitivity of tumor cell lines to the mTOR pathway inhibitor RAD001 [abstract B170]. Clin Cancer Res 2003;9
   Google Scholar
• Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91
   PubMed Web of Science ®Google Scholar
• Haritunians T, Mori A, O'Kelly J, et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007;21:333-9
   PubMed Web of Science ®Google Scholar
• Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007;25:4806-12
   PubMed Web of Science ®Google Scholar
• Gomez-Camarero J, Salcedo M, Rincon D, et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007;84:786-91
   PubMed Web of Science ®Google Scholar
• de Fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007;22 (Suppl 1):i23-6
   PubMed Web of Science ®Google Scholar
• Ruiz JC, Sánchez A, Rengel M, et al. EVERODATA Group. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. Transplant Proc 2007;39:2157-9
   PubMed Web of Science ®Google Scholar
• Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003;75:1710-7
   PubMed Web of Science ®Google Scholar
• Jundt F, Raetzel N, Müller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappa B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005;106:1801-7
   PubMed Web of Science ®Google Scholar
• Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007;85:54-60
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-70
   PubMed Web of Science ®Google Scholar